NASDAQ:NVNO enVVeno Medical Q1 2025 Earnings Results & Report $5.95 -0.22 (-3.57%) Closing price 04:00 PM EasternExtended Trading$5.91 -0.04 (-0.67%) As of 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. enVVeno Medical reported Q1 2025 earnings on April 30, 2025. The company reported EPS of -$7.70. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateApril 30, 2025TimeAfter Market Closes enVVeno Medical EPS ResultsActual EPS-$7.70Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate2 of last 6 quartersenVVeno Medical Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile enVVeno Medical Q1 2025 Earnings FAQ Did enVVeno Medical beat earnings estimates for Q1 2025? enVVeno Medical (NASDAQ:NVNO) reported earnings of -$7.70 per share for Q1 2025. The report was announced on Wednesday, April 30, 2025. enVVeno Medical Earnings HeadlinesenVVeno Medical to present its enVVE System at annual TCTNovember 2, 2026 | tipranks.comenVVeno Medical Corporation: enVVeno Medical Reports Third Quarter 2026 Financial Results and Prepares to Treat First Patients in FDA-Approved TAVVE Pivotal StudyOctober 30, 2026 | finanznachrichten.deI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 16 at 1:00 AM | Behind the Markets (Ad)enVVeno Medical Releases New Episode of "WTF" Video Series Featuring CEO Rob BermanOctober 21, 2026 | finance.yahoo.comenVVeno Medical Corporation: enVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal TrialOctober 2, 2026 | finanznachrichten.deenVVeno Medical Corporation: enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video SeriesSeptember 16, 2026 | finanznachrichten.deSee More enVVeno Medical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like enVVeno Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on enVVeno Medical and other key companies, straight to your email. Email Address About enVVeno MedicalenVVeno Medical (NASDAQ:NVNO) is a medical-device company developing treatments for chronic venous disease, with a focus on deep venous chronic venous insufficiency. This condition can occur when valves in the leg’s deep veins do not function properly, impairing blood flow back to the heart. The company’s lead product, VenoValve, is a bioprosthetic valve designed to restore valve function in affected deep veins. enVVeno has also described a transcatheter valve program, enVVe, intended to provide a less invasive approach to treating the condition. Previously known as Hancock Jaffe Laboratories, the company adopted the enVVeno Medical name in 2021. It is based in Irvine, California, and its development efforts are directed primarily toward the U.S. market.View enVVeno Medical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/133 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCould Big Buybacks Be the Next Catalyst for These 3 AI Stocks?Cerebras Q3 Results: How Much More Proof Does Wall Street Need? Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.